Askenazi DJ, Heagerty PJ, Schmicker RH, et al. - In this ancillary analysis to a multicenter double-blind, placebo-controlled randomized clinical trial, researchers investigated if better or worse kidney-related results during hospitalization and at 22-26 months corrected gestational age (cGA) were reported in extremely low gestational age neonates (ELGANs) randomized to erythropoietin vs those randomized to placebo. For severe (stage 2 or 3) acute kidney injury (AKI), the estimated prevalence was 18.2%. In terms of in-hospital primary (severe AKI) or secondary outcomes (any AKI and serum creatinine/ cystatin C values at days 0, 7, 9 and 14), there was no statistically significant difference between the two groups. Findings revealed high rates of in-hospital AKI in ELGANs as well as the presence of kidney-related issues at 22-26 months cGA. In ELGANs, long-term elevated systolic blood pressure may be prevented by treatment with recombinant erythropoietin, however, it did not seem effective to avoid AKI, low estimated glomerular filtration rate, albuminuria or elevated diastolic blood pressure at 22-26 months cGA.